Headlines for [GENZ]

• GENZ 11/24/2008 11:32am
  Genzyme Corp Files supplemental NDA with FDA for use of Clolar to treat patients with acute myeloid leukemia- The company has requested priority review of its application and, if granted, Clolar could be approved more...
  
• GENZ 11/17/2008 04:05pm
  Genzyme Corp Forms Collaboration with International Center for Genetic Engineering and Biotechnology to Advance Treatments for Neglected Diseases- The collaboration between Genzyme and ICGEB will initially focus more...
  
• GENZ 11/17/2008 09:03am
  Genzyme Corp Reconfirms FY 2009 EPS guidance of $4.70 v $4.74e- Announces that the FDA plans an Accelerated Approval for Myozyme produced at the 2000 L bioreactor scale for the treatment of late Onset Pompe more...
  
• OSIR 11/4/2008 07:45am
  Osiris Therapeutics Inc Partners with Genyme to develop and commercialize adult stem cell products, sees $130M upfront payment- Entered into strategic alliance for the development and commercialization of Prochymal and more...
  
• GENZ 10/22/2008 06:52pm
  Genzyme Corp Price Target lowered to $88 from $93 at Merrill, maintains buy rating
  

Healthcare sector headlines

• NPSP Today 08:50am
  NPS Pharmaceuticals Inc. Update: Initiates Phase 3 'STEPS' Study to Confirm GATTEX Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome- Patient enrollment has begun in a Phase 3 registrational study to confirm more...
  
• OCLS Today 08:48am
  Oculus Innovative Sciences Update: Signs development agreement with Bayer Taiwan for Microcyn tech in Taiwanese animal market- As part of the agreement, Bayer Taiwan Co. Ltd. will be responsible for securing Taiwanese more...
  
• TPTX Today 08:47am
  TorreyPines Therapeutics Update: Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia- Announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as more...
  
• CUR Today 08:02am
  Neuralstem Inc Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials- The collaboration will focus on Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with Dr. more...
  
• SVA Today 08:01am
  Sinovac Biotech Announces share buyback of up to $2M (5.5% of market cap)